Unicycive Therapeutics Statistics
Total Valuation
UNCY has a market cap or net worth of $67.18 million. The enterprise value is $51.11 million.
Important Dates
The next confirmed earnings date is Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UNCY has 119.71 million shares outstanding. The number of shares has increased by 196.89% in one year.
| Current Share Class | 119.71M |
| Shares Outstanding | 119.71M |
| Shares Change (YoY) | +196.89% |
| Shares Change (QoQ) | +17.14% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 17.26% |
| Float | 70.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.28 |
| P/TBV Ratio | 6.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.64 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -468.21 |
Financial Efficiency
Return on equity (ROE) is -92.09% and return on invested capital (ROIC) is -112.73%.
| Return on Equity (ROE) | -92.09% |
| Return on Assets (ROA) | -48.08% |
| Return on Invested Capital (ROIC) | -112.73% |
| Return on Capital Employed (ROCE) | -274.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$708,304 |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.78% in the last 52 weeks. The beta is 2.13, so UNCY's price volatility has been higher than the market average.
| Beta (5Y) | 2.13 |
| 52-Week Price Change | -48.78% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 42.80 |
| Average Volume (20 Days) | 585,690 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.90M |
| Pretax Income | -36.93M |
| Net Income | -16.29M |
| EBITDA | -30.88M |
| EBIT | -30.90M |
| Earnings Per Share (EPS) | -$0.26 |
Full Income StatementBalance Sheet
The company has $19.77 million in cash and $548,000 in debt, giving a net cash position of $19.22 million or $0.16 per share.
| Cash & Cash Equivalents | 19.77M |
| Total Debt | 548,000 |
| Net Cash | 19.22M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 11.27M |
| Book Value Per Share | 0.09 |
| Working Capital | 10.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.02 million and capital expenditures -$82,000, giving a free cash flow of -$31.10 million.
| Operating Cash Flow | -31.02M |
| Capital Expenditures | -82,000 |
| Free Cash Flow | -31.10M |
| FCF Per Share | -$0.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |